Roxane Laboratories, Inc. Announces the Launch of Mycophenolate Mofetil 250mg Capsules and 500... ( COLUMBUS Ohio May 4 /- Roxane Laborat...)

Roxane Laboratories, Inc. Announces the Launch of Mycophenolate Mofetil 250mg Capsules and 500mg Tablets

Date:5/4/2009

COLUMBUS, Ohio, May 4 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the launch of its generic for Mycophenolate Mofetil 250mg Capsules and 500mg Tablets by the U.S. Food and Drug Administration. These products are available in 250mg Capsules Bottles of 100 and 500, 500mg Tablets Bottles of 100 and 500. These products are available for immediate shipment to wholesalers and pharmacies nationwide.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090504/CL10321)

Roxane Laboratories' Mycophenolate Mofetil 250mg Capsules and 500mg Tablets, are AB rated to CellCept(R) (mycophenolate mofetil) capsules and tablets. Annual sales of Mycophenolate Mofetil are approximately $1,017 Million(1).

Full prescribing information for Mycophenolate Mofetil Capsules and Tablets is available on the Roxane Laboratories website at www.Roxane.com or upon request by calling Roxane Laboratories Technical Product Information at 1.800.962.8364.

About Roxane Laboratories, Inc.

Roxane Laboratories is located in Columbus, OH in a modern 500,000 square foot manufacturing and laboratory facility. The facility spans 70 acres and currently employs over 1,000 people. Currently, Roxane Laboratories markets over 80 medications in nearly 250 package sizes, focusing on an expanding line of Multisource pharmaceutical products including: bulk and unit-dose liquids and solids; coated, sustained-release and controlled- release tablets; nasal sprays, cytotoxics and CII narcotics.

Roxane Laboratories, Inc., is a subsidiary of Boehringer Ingelheim Corporation, based in Ridgefield, CT and a member of the Boehringer Ingelheim group of companies.

About Boehringer Ingelheim

Boehringer Ingelheim Corporation based in Ri
'/>"/>

0

GOOD

Page: 1 2
Related biology technology :

1. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
2. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
3. Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems
4. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
5. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
6. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
7. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
8. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 First Quarter Earnings
9. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation from Board of Directors of Jitendra Doshi and Appointment of GP Singh Sachdeva
10. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009
11. Getting Ready Corporation and Winston Laboratories, Inc. Announce Completion of Merger

Post Your Comments:

Roxane Laboratories, Inc. Announces the Launch of Mycophenolate Mofetil 250mg Capsules and 500...( COLUMBUS Ohio May 4 /- Roxane Laborat...)